Drug Approval | December 03, 2025
LENZ Therapeutics, Lotus Pharmaceutical submit NDA for presbyopia treatment in Korea
Presbyopia, the age-related loss of near vision, could soon be treated successfully
Presbyopia, the age-related loss of near vision, could soon be treated successfully
Despite steep funding setbacks, the global HIV response has gained momentum in 2025 with the introduction of twice-yearly injectable LEN
StarGuide GX delivers ultra-high sensitivity and high-resolution imaging, enabling fast, confident diagnostics
Ilumya is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials
Roche says the move marks a step forward in its digital transformation strategy
Phase one of the expansion will convert an existing hall into an ISO 7-certified cleanroom for GMP-compliant production
In 2024, 59 countries reported large or disruptive measles outbreaks – nearly triple the number reported in 2021 and the highest since the onset of the COVID-19 pandemic
Selected proposals in the innovation challenge will receive funding to develop transformative ideas, tools, and approaches to strengthen early diagnosis and improve patient outcomes
Ascelis Center of Excellence for Peptide Development and Characterization will drive the development of cosmetic, therapeutic, and pharmaceutical peptides
This distinction is testament to LHWRF's dedication to excellence, transparency, and impact in the realm of social responsibility
Subscribe To Our Newsletter & Stay Updated
